APAC Gene Therapy Market

APAC Gene Therapy Market Size (2023 to 2028)

The gene therapy market in the Asia-Pacific is expected to witness the fastest CAGR of 32.46% during the forecast period. As a result, the market size is anticipated to be valued at USD 6.53 billion by 2028 from USD 1.6 billion in 2023.

The growing population suffering from chronic diseases such as cancer across the Asia-Pacific region is one of the major factors propelling the gene therapy market in APAC. Cancer gene therapy is the most successful for various cancers, such as head, neck, lung, hepatocellular, and others. Gene transfer is the new way of treatment for the slow growth or prevention of cancer in patients. This treatment has given more successful outcomes in recent years, leading to market growth. The process works as the transferred gene helps to kill the cancerous cell and manage the disease.

The growing incidence of infectious diseases among the population of the APAC region is another major factor boosting the APAC gene therapy market growth. Gene therapy can treat infectious diseases such as HIV and hepatitis B. Research on gene therapy is primarily done in China. Gene-based clinical trials are primarily used for understanding the disease's pathogenesis and will improve the therapy outcome for common diseases.

The rising number of approvals for gene therapy products is further promoting the gene therapy market in the Asia-Pacific region. Owing to the growing favorable outcomes of gene therapy, the government is focused on the approvals of gene-related products, which may lead to rising life expectancy among patients. In addition, the approval of the drugs for gene therapy has several steps and strict guidelines to avoid severe side effects when used for treatment.

Furthermore, the increasing number of investments in the R&D of gene therapy is supporting the gene therapy market in the Asia-Pacific region. Many gene therapy technologies have been used in clinical trials for research purposes. In addition, many key players, government, public and private sectors, are increasing their investment in gene therapy products and treatment, leading to market growth.

However, high costs associated with gene therapy are majorly hampering the market growth in APAC. Furthermore, the lengthy developmental period of gene therapy and approvals hamper the market growth. In addition, the scarcity of skilled professionals who can handle gene therapy operations in Asia-Pacific impedes market growth in this region. Furthermore, side effects associated with gene therapy are anticipated to inhibit market growth in the coming years.

This research report on the Asia-Pacific gene therapy market has been segmented & sub-segmented into the following categories:

 By Vector Type:

• Viral vector
  • Retroviruses
  • Lentiviruses
  • Adenoviruses
  • Adeno-associated Virus
  • Herpes Simplex Virus
  • Poxvirus
  • Vaccinia Virus
  • Others
• Non-viral vector
  • Naked/Plasmid Vectors
  • Gene Gun
  • Electroporation
  • Lipofection
  • Others

By Application:

• Oncological Disorders
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Infectious disease
• Other Diseases

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the Asia Pacific gene therapy market is estimated to be the fastest-growing region globally during the forecast period due to the factors such as the growing population suffering from chronic diseases, the increasing aging population, and rising disposable income. In addition, the growing number of start-ups in the field of gene therapy in Asia manufacturing various gene therapy products favors regional market growth. China and Japan have accounted for a notable share of the Asia-Pacific region in 2021, owing to the growing R&D activities around gene therapy. Due to increasing cases of hemophilia in China among males, China's government decided to increase research on the disease and found a gene therapy treatment that helps provide a fast cure and prevent the disease in the patients.

The Chinese gene therapy market is forecasted to register the highest CAGR in the APAC market during the forecast period. Gene therapies have brought a revolutionary change in health science and pharmaceuticals in China, replacing dysfunctional genes that cause disease to re-establish normal function. In addition, factors such as researchers in the China region boost their activities and the high prevalence of cancer, expanding the gene therapy market in China.

The Indian gene therapy market is one of the fastest-growing regional markets in the APAC market. The growing number of people diagnosed with chronic diseases, the presence of a growing number of market participants and increasing investments from the government, and improving healthcare infrastructure are propelling India's market growth. In addition, there are some guidelines for the development of gene therapy in the "National Guidelines Held for Gene Therapy Product (GTP) Development and Clinical Trials" prepared by the Indian Council of Medical Research and the Department of Biotechnology in 2019. This guideline helps in advancing gene therapy research and its new drug approvals.

The Japanese market is projected to account for a moderate share during the forecast period in this regional market. The high prevalence rate of cancer, advancing therapies, and gene delivery technologies are contributing to Japan's gene therapy market's growth.

KEY MARKET PLAYERS:

Companies playing a significant role in the APAC gene therapy market profiled in this report are Biogen, Sarepta Therapeutics, Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Orchard Therapeutics Plc, Spark Therapeutics, Inc., Molmed S.P.A., Anges, Inc., Bluebird Bio, Inc., Jazz Pharmaceuticals Plc, Dynavax Technologies, Human Stem Cells Institute, Sibiono Genetech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Uniqure N.V., Gensight Biologics S.A., Celgene Corporation, Cellectis, Sangamo Therapeutics, Mustang Bio, Applied Genetic Technologies Corporation and Poseida Therapeutics, Inc.